OnlyFans model and cosplayer Mikomi Hokina has become the subject of renewed attention this week after her 2022 breast cancer diagnosis, confirmed hours before she was due to fly to Thailand for a shoot, resurfaced across entertainment outlets, as reported in Creatorzine.

Hokina Discovers Breast Lump During OnlyFans Shoot

Hokina, then 26, was filming with a co-star when the co-star touched her chest and felt what Hokina later described as a small, rock-like lump. According to PCGamesN, which interviewed her directly, a biopsy soon after confirmed triple-negative breast cancer, an aggressive but chemotherapy-responsive subtype.

She had already known she carried a harmful BRCA1 variant, tested after her mother died of breast cancer. Describing how quickly treatment began once she returned from Thailand, she told the PCGamesN, "By March 28 I was doing my first chemotherapy session."

BRCA1 Diagnosis Confirmed Before Thailand Trip

The biopsy results confirming cancer arrived about two hours before Hokina was due to board a flight to Thailand for another shoot. She travelled anyway on medical advice, and hospital appointments began as soon as she returned to Belgium. Her first chemotherapy session started on March 28, about a month after her diagnosis on February 27.

In a Twitter thread posted around the time of her diagnosis, she told followers,

"To make it short: I will go under 16 cures of chemotherapy across the next 5-6 months and have surgery at the end. It's caught at early stage, and I'm young so hopefully, my life will just go on normally after."

In the same post, she explained that her mother had died of breast cancer about five years earlier, after carrying the same genetic mutation Hokina later tested positive for herself. The cancer was triple-negative breast cancer, an aggressive but chemotherapy-responsive subtype. As she initially planned, the treatment plan included 16 rounds of chemotherapy followed by surgery, a bilateral mastectomy with reconstructive implants, in late 2022.

Hair Loss, Cosplay, and a Saitama Comeback

Much of Hokina's income and public identity is built around cosplay, a craft that relies heavily on wigs, makeup, and closely matching a character's features. She noted that her first thought after the diagnosis was simply that she would have to work twice as hard to keep creating content while navigating the intense fatigue of treatment.

She later described losing her eyebrows during chemotherapy as harder to accept than losing her hair; a bald head could be styled deliberately, whereas missing eyebrows felt unmistakably like a clinical marker of illness.

Hokina was declared cancer-free in September 2022. She marked the milestone with a celebratory cosplay photoshoot as Saitama, the bald protagonist of the anime One-Punch Man, turning her hair loss into a fitting tribute to a character famous for effortlessly defeating any opponent.

On the one-year anniversary of her diagnosis, in a separate post, she urged her followers to fight, stand up strong, and to never give up."

What BRCA1 Means for Breast Cancer Risk

BRCA1 (BReast CAncer gene 1) normally helps repair damaged DNA, and a harmful variant disables that function, sharply raising cancer risk: carriers face a lifetime breast cancer risk of roughly 55 to 72 percent, versus about 12 to 13 percent in the general population,¹^,² along with a substantially higher ovarian cancer risk and a more modest rise in pancreatic and colon cancer risk,³ and BRCA1-linked cancers tend to appear earlier than usual cases, often before natural menopause, as in Hokina's diagnosis at 26.¹^,² Incidental discovery of a lump by someone other than the patient, as happened on set, is not unusual, since self-examination has known limits on sensitivity and a second, less familiar pair of hands can register a change the patient has normalised over time. Genetic testing for BRCA1/BRCA2 is not recommended as a general population screen but is advised for those with early-onset breast cancer, cancer in both breasts, a family history of ovarian cancer, or a known mutation in a relative; a child of a carrier has a 50 percent chance of inheriting the variant, making cascade testing of relatives standard practice,¹ ideally pursued through a clinical genetics unit with pre- and post-test counselling, in India in line with ICMR guidance,⁴ rather than through direct-to-consumer kits.

References

1. National Cancer Institute. "BRCA1 and BRCA2: Cancer Risk and Genetic Testing." PDQ Cancer Genetics Editorial Board. National Cancer Institute, Bethesda, MD. https://www.ncbi.nlm.nih.gov/books/NBK545871/

2. Kuchenbaecker, K. B., J. L. Hopper, D. R. Barnes, et al. "Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers." JAMA 317, no. 23 (2017): 2402–2416. https://doi.org/10.1001/jama.2017.7112.

3. Kotsopoulos, J., A. I. Apostol, K. Metcalfe, et al. "The Risk of Breast Cancer According to Mutation Type and Position in Carriers of a Pathogenic Variant in BRCA1." Current Oncology 32, no. 12 (2025): 705. https://doi.org/10.3390/curroncol32120705.

4. Indian Council of Medical Research. Consensus Document for Management of Breast Cancer. ICMR, New Delhi. pdf

(Rh/AK/MSM)